Your Messages Inbox
Your Article Summary
See Latest ArticlesNew Precaution Concerning Leukotriene Inhibitors
American Journal of Nursing, 10/01/09
Aschenbrenner DS – The FDA has requested that the product labeling for leukotriene inhibitors include a precaution that neuropsychiatric events have been reported in some patients taking the drugs. The agency is advising health care providers and patients to be aware that these reported adverse effects might occur.
Related Articles
MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: Synergistic action with LY294002, an inhibitor of phosphatidylinositol 3?-kinase
Cancer Letters, 11/16/09
Relevance Score: 80%
Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor
Journal of Experimental Medicine, 10/28/09
Relevance Score: 80%
Regulation of TNFalpha and IL1beta in rheumatoid arthritis synovial fibroblasts by leukotriene B4
Rheumatology International, 10/27/09
Relevance Score: 80%
Leukotriene B4 Contributes to Exhaled Breath Condensate and Sputum Neutrophil Chemotaxis in COPD
Chest, 10/14/09
Relevance Score: 80%
Targeting Leukotrienes for the Treatment of COPD
Inflammation & Allergy - Drug Targets, 10/12/09
Relevance Score: 80%
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals
PLoS Medicine, 12/02/09
FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09
Article Search
Sponsor